Ubiquitin-mediated proteasomal degradation in normal and malignant hematopoiesis

Blood Cells, Molecules, and Diseases

Volumn 40, Issue 2, 2008, Pages 200-210

  Heuzé, Mélina L ^a   Lamsoul, Isabelle ^a   Moog Lutz, Christel ^a,b   Lutz, Pierre G ^a  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

E3 ligase; Hematopoiesis; Leukemogenesis; Proteasome; Ubiquitin

Indexed keywords

PROTEASOME; UBIQUITIN;

ARTICLE; CARCINOGENESIS; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; LEUKEMOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION;

HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HEMATOPOIETIC SYSTEM; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; RING FINGER DOMAINS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASE COMPLEXES; UBIQUITIN-PROTEIN LIGASES;

EID: 38949189642     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2007.07.011     Document Type: Article

References (185)

1. Bonifacino J.S., and Traub L.M. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Ann. Rev. Biochem. 72 (2003) 395-447
2. Welchman R.L., Gordon C., and Mayer R.J. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat. Rev., Mol. Cell Biol. 6 (2005) 599-609
3. Pickart C.M., and Fushman D. Polyubiquitin chains: polymeric protein signals. Curr. Opin. Chem. Biol. 8 (2004) 610-616
4. Koegl M., Hoppe T., Schlenker S., et al. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96 (1999) 635-644
5. Hoppe T. Multiubiquitylation by E4 enzymes: 'one size' doesn't fit all. Trends Biochem. Sci. 30 (2005) 183-187
6. Nijman S.M., Luna-Vargas M.P., Velds A., et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 123 (2005) 773-786
7. Pickart C.M., and Cohen R.E. Proteasomes and their kin: proteases in the machine age. Nat. Rev., Mol. Cell Biol. 5 (2004) 177-187
8. Ciechanover A., and Schwartz A.L. The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochim. Biophys. Acta 1695 (2004) 3-17
9. Dicato M., Boccadoro M., Cavenagh J., et al. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Oncology 70 (2006) 474-482
10. Nakayama K.I., and Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev., Cancer 6 (2006) 369-381
11. Huibregtse J.M., Scheffner M., Beaudenon S., and Howley P.M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 2563-2567
12. Scheffner M., Nuber U., and Huibregtse J.M. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373 (1995) 81-83
13. Shearwin-Whyatt L., Dalton H.E., Foot N., and Kumar S. Regulation of functional diversity within the Nedd4 family by accessory and adaptor proteins. BioEssays 28 (2006) 617-628
14. Liu Y.C. The E3 ubiquitin ligase Itch in T cell activation, differentiation, and tolerance. Semin. Immunol. 19 (2007) 197-205
15. Fang D., Elly C., Gao B., et al. Dysregulation of T lymphocyte function in itchy mice: a role for Itch in TH2 differentiation. Nat. Immunol. 3 (2002) 281-287
16. Gao M., Labuda T., Xia Y., et al. Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science 306 (2004) 271-275
17. Yang C., Zhou W., Jeon M.S., et al. Negative regulation of the E3 ubiquitin ligase itch via Fyn-mediated tyrosine phosphorylation. Mol. Cell 21 (2006) 135-141
18. Fortunel N.O., Hatzfeld A., and Hatzfeld J.A. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 96 (2000) 2022-2036
19. Hu X., and Zuckerman K.S. Transforming growth factor: signal transduction pathways, cell cycle mediation, and effects on hematopoiesis. J. Hematother. Stem. Cell Res. 10 (2001) 67-74
20. Massague J. TGF-beta signal transduction. Ann. Rev. Biochem. 67 (1998) 753-791
21. Whitman M. Smads and early developmental signaling by the TGFbeta superfamily. Genes Dev. 12 (1998) 2445-2462
22. Derynck R., Akhurst R.J., and Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29 (2001) 117-129
23. Moustakas A., Souchelnytskyi S., and Heldin C.H. Smad regulation in TGF-beta signal transduction. J. Cell Sci. 114 (2001) 4359-4369
24. Attisano L., and Wrana J.L. Signal transduction by the TGF-beta superfamily. Science 296 (2002) 1646-1647
25. Shi Y., and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
26. Wrana J.L., Attisano L., Wieser R., et al. Mechanism of activation of the TGF-beta receptor. Nature 370 (1994) 341-347
27. Piek E., Heldin C.H., and Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J. 13 (1999) 2105-2124
28. Heldin C.H., Miyazono K., and ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390 (1997) 465-471
29. Abdollah S., Macias-Silva M., Tsukazaki T., et al. TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J. Biol. Chem. 272 (1997) 27678-27685
30. Nakao A., Imamura T., Souchelnytskyi S., et al. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 16 (1997) 5353-5362
31. Nishimura R., Kato Y., Chen D., et al. Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J. Biol. Chem. 273 (1998) 1872-1879
32. Derynck R., Zhang Y., and Feng X.H. Smads: transcriptional activators of TGF-beta responses. Cell 95 (1998) 737-740
33. Briones-Orta M.A., Sosa-Garrocho M., Moreno-Alvarez P., et al. SnoN co-repressor binds and represses smad7 gene promoter. Biochem. Biophys. Res. Commun. 341 (2006) 889-894
34. He J., Tegen S.B., Krawitz A.R., et al. The transforming activity of Ski and SnoN is dependent on their ability to repress the activity of Smad proteins. J. Biol. Chem. 278 (2003) 30540-30547
35. Liu X., Sun Y., Weinberg R.A., and Lodish H.F. Ski/Sno and TGF-beta signaling. Cytokine Growth Factor Rev. 12 (2001) 1-8
36. Luo K. Ski and SnoN: negative regulators of TGF-beta signaling. Curr. Opin. Genet. Dev. 14 (2004) 65-70
37. ten Dijke P., Miyazono K., and Heldin C.H. Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem. Sci. 25 (2000) 64-70
38. Attisano L., and Wrana J.L. Smads as transcriptional co-modulators. Curr. Opin. Cell Biol. 12 (2000) 235-243
39. ten Dijke P., and Hill C.S. New insights into TGF-beta-Smad signalling. Trends Biochem. Sci. 29 (2004) 265-273
40. Nakao A., Afrakhte M., Moren A., et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389 (1997) 631-635
41. Imamura T., Takase M., Nishihara A., et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature 389 (1997) 622-626
42. Dickson M.C., Martin J.S., Cousins F.M., et al. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 121 (1995) 1845-1854
43. Borkowski T.A., Letterio J.J., Mackall C.L., et al. A role for TGFbeta1 in langerhans cell biology. Further characterization of the epidermal Langerhans cell defect in TGFbeta1 null mice. J. Clin. Invest. 100 (1997) 575-581
44. Oshima M., Oshima H., and Taketo M.M. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev. Biol. 179 (1996) 297-302
45. Shull M.M., Ormsby I., Kier A.B., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359 (1992) 693-699
46. Kulkarni A.B., Huh C.G., Becker D., et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 770-774
47. Letterio J.J., Geiser A.G., Kulkarni A.B., et al. Maternal rescue of transforming growth factor-beta 1 null mice. Science 264 (1994) 1936-1938
48. Ottmann O.G., and Pelus L.M. Differential proliferative effects of transforming growth factor-beta on human hematopoietic progenitor cells. J. Immunol. 140 (1988) 2661-2665
49. Sing G.K., Keller J.R., Ellingsworth L.R., and Ruscetti F.W. Transforming growth factor beta selectively inhibits normal and leukemic human bone marrow cell growth in vitro. Blood 72 (1988) 1504-1511
50. Keller J.R., McNiece I.K., Sill K.T., et al. Transforming growth factor beta directly regulates primitive murine hematopoietic cell proliferation. Blood 75 (1990) 596-602
51. Jacobsen S.E., Ruscetti F.W., Dubois C.M., et al. Transforming growth factor-beta trans-modulates the expression of colony stimulating factor receptors on murine hematopoietic progenitor cell lines. Blood 77 (1991) 1706-1716
52. Sitnicka E., Ruscetti F.W., Priestley G.V., et al. Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells. Blood 88 (1996) 82-88
53. Batard P., Monier M.N., Fortunel N., et al. TGF-(beta)1 maintains hematopoietic immaturity by a reversible negative control of cell cycle and induces CD34 antigen up-modulation. J. Cell Sci. 113 Pt 3 (2000) 383-390
54. Keller J.R., Jacobsen S.E., Sill K.T., et al. Stimulation of granulopoiesis by transforming growth factor beta: synergy with granulocyte/macrophage-colony-stimulating factor. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 7190-7194
55. Turley J.M., Falk L.A., Ruscetti F.W., et al. Transforming growth factor beta 1 functions in monocytic differentiation of hematopoietic cells through autocrine and paracrine mechanisms. Cell Growth Differ. 7 (1996) 1535-1544
56. Jackson H., Williams N., Westcott K.R., and Green R. Differential effects of transforming growth factor-beta 1 on distinct developmental stages of murine megakaryocytopoiesis. J. Cell. Physiol. 161 (1994) 312-318
57. Berthier R., Valiron O., Schweitzer A., and Marguerie G. Serum-free medium allows the optimal growth of human megakaryocyte progenitors compared with human plasma supplemented cultures: role of TGF beta. Stem Cells 11 (1993) 120-129
58. Kuter D.J., Gminski D.M., and Rosenberg R.D. Transforming growth factor beta inhibits megakaryocyte growth and endomitosis. Blood 79 (1992) 619-626
59. Cowley S.A., Groopman J.E., and Avraham H. Effects of transforming growth factor beta on megakaryocytic cell fusion and endomitosis. Int. J. Cell Cloning 10 (1992) 223-231
60. Bhatia M., Bonnet D., Wu D., et al. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. J. Exp. Med. 189 (1999) 1139-1148
61. Liu B., Sun Y., Jiang F., et al. Disruption of Smad5 gene leads to enhanced proliferation of high-proliferative potential precursors during embryonic hematopoiesis. Blood 101 (2003) 124-133
62. Bruno E., Horrigan S.K., Van Den Berg D., et al. The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. Blood 91 (1998) 1917-1923
63. Izzi L., and Attisano L. Regulation of the TGFbeta signalling pathway by ubiquitin-mediated degradation. Oncogene 23 (2004) 2071-2078
64. Zhu H., Kavsak P., Abdollah S., et al. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400 (1999) 687-693
65. Murakami G., Watabe T., Takaoka K., et al. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol. Biol. Cell 14 (2003) 2809-2817
66. Bonni S., Wang H.R., Causing C.G., et al. TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat. Cell Biol. 3 (2001) 587-595
67. Zhang Y., Chang C., Gehling D.J., et al. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 974-979
68. Lin X., Liang M., and Feng X.H. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J. Biol. Chem. 275 (2000) 36818-36822
69. Li H., and Seth A. An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein. Oncogene 23 (2004) 1801-1808
70. Itoh F., Asao H., Sugamura K., et al. Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J. 20 (2001) 4132-4142
71. Moren A., Imamura T., Miyazono K., et al. Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. J. Biol. Chem. 280 (2005) 22115-22123
72. Ebisawa T., Fukuchi M., Murakami G., et al. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276 (2001) 12477-12480
73. Kavsak P., Rasmussen R.K., Causing C.G., et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol. Cell 6 (2000) 1365-1375
74. Woolf E., Xiao C., Fainaru O., et al. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 7731-7736
75. Hanai J., Chen L.F., Kanno T., et al. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J. Biol. Chem. 274 (1999) 31577-31582
76. Kuratomi G., Komuro A., Goto K., et al. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. Biochem. J. 386 (2005) 461-470
77. Seo S.R., Lallemand F., Ferrand N., et al. The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. EMBO J. 23 (2004) 3780-3792
78. Komuro A., Imamura T., Saitoh M., et al. Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). Oncogene 23 (2004) 6914-6923
79. Freemont P.S. The RING finger. A novel protein sequence motif related to the zinc finger. Ann. N. Y. Acad. Sci. 684 (1993) 174-192
80. Zheng N., Wang P., Jeffrey P.D., and Pavletich N.P. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 102 (2000) 533-539
81. van der Reijden B.A., Erpelinck-Verschueren C.A., Lowenberg B., and Jansen J.H. TRIADs: a new class of proteins with a novel cysteine-rich signature. Protein Sci. 8 (1999) 1557-1561
82. Morett E., and Bork P. A novel transactivation domain in parkin. Trends Biochem. Sci. 24 (1999) 229-231
83. Marteijn J.A., van Emst L., Erpelinck-Verschueren C.A., et al. The E3 ubiquitin-protein ligase Triad1 inhibits clonogenic growth of primary myeloid progenitor cells. Blood 106 (2005) 4114-4123
84. Chuang T.H., and Ulevitch R.J. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat. Immunol. 5 (2004) 495-502
85. Chen D., Li X., Zhai Z., and Shu H.B. A novel zinc finger protein interacts with receptor-interacting protein (RIP) and inhibits tumor necrosis factor (TNF)- and IL1-induced NF-kappa B activation. J. Biol. Chem. 277 (2002) 15985-15991
86. Fearns C., Pan Q., Mathison J.C., and Chuang T.H. Triad3A regulates ubiquitination and proteasomal degradation of RIP1 following disruption of Hsp90 binding. J. Biol. Chem. 281 (2006) 34592-34600
87. Zhao H., Li C.C., Pardo J., et al. A novel E3 ubiquitin ligase TRAC-1 positively regulates T cell activation. J. Immunol. 174 (2005) 5288-5297
88. Anandasabapathy N., Ford G.S., Bloom D., et al. GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells. Immunity 18 (2003) 535-547
89. Seroogy C.M., Soares L., Ranheim E.A., et al. The gene related to anergy in lymphocytes, an E3 ubiquitin ligase, is necessary for anergy induction in CD4 T cells. J. Immunol. 173 (2004) 79-85
90. Swaminathan G., and Tsygankov A.Y. The Cbl family proteins: ring leaders in regulation of cell signaling. J. Cell. Physiol. 209 (2006) 21-43
91. Rao N., Ghosh A.K., Ota S., et al. The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation. EMBO J. 20 (2001) 7085-7095
92. Paolini R., Molfetta R., Piccoli M., et al. Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9611-9616
93. Paolini R., Molfetta R., Beitz L.O., et al. Activation of Syk tyrosine kinase is required for c-Cbl-mediated ubiquitination of Fcepsilon RI and Syk in RBL cells. J. Biol. Chem. 277 (2002) 36940-36947
94. Kyo S., Sada K., Qu X., et al. Negative regulation of Lyn protein-tyrosine kinase by c-Cbl ubiquitin-protein ligase in Fc epsilon RI-mediated mast cell activation. Genes Cells 8 (2003) 825-836
95. Howlett C.J., and Robbins S.M. Membrane-anchored Cbl suppresses Hck protein-tyrosine kinase mediated cellular transformation. Oncogene 21 (2002) 1707-1716
96. Xiong H., Li H., Kong H.J., et al. Ubiquitin-dependent degradation of interferon regulatory factor-8 mediated by Cbl down-regulates interleukin-12 expression. J. Biol. Chem. 280 (2005) 23531-23539
97. Magnifico A., Ettenberg S., Yang C., et al. WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation. J. Biol. Chem. 278 (2003) 43169-43177
98. Larsson J., and Karlsson S. The role of Smad signaling in hematopoiesis. Oncogene 24 (2005) 5676-5692
99. Koinuma D., Shinozaki M., Komuro A., et al. Arkadia amplifies TGF-beta superfamily signalling through degradation of Smad7. EMBO J. 22 (2003) 6458-6470
100. Nagano Y., Mavrakis K.J., Lee K.L., et al. Arkadia induces degradation of SnoN and c-Ski to enhance TGF-beta signaling. J. Biol. Chem. 282 (2007) 20492-20501
101. Mavrakis K.J., Andrew R.L., Lee K.L., et al. Arkadia enhances Nodal/TGF-beta signaling by coupling Phospho-Smad2/3 activity and turnover. PLoS Biol. 5 (2007) e67
102. Petroski M.D., and Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev., Mol. Cell Biol. 6 (2005) 9-20
103. Gao M., and Karin M. Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli. Mol. Cell 19 (2005) 581-593
104. Wu K., Chen A., and Pan Z.Q. Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. J. Biol. Chem. 275 (2000) 32317-32324
105. Bottero V., Withoff S., and Verma I.M. NF-kappaB and the regulation of hematopoiesis. Cell Death Differ. 13 (2006) 785-797
106. Yaron A., Hatzubai A., Davis M., et al. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 396 (1998) 590-594
107. Winston J.T., Strack P., Beer-Romero P., et al. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 13 (1999) 270-283
108. Spencer E., Jiang J., and Chen Z.J. Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP. Genes Dev. 13 (1999) 284-294
109. Kroll M., Margottin F., Kohl A., et al. Inducible degradation of IkappaBalpha by the proteasome requires interaction with the F-box protein h-betaTrCP. J. Biol. Chem. 274 (1999) 7941-7945
110. Hatakeyama S., Kitagawa M., Nakayama K., et al. Ubiquitin-dependent degradation of IkappaBalpha is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3859-3863
111. Kitagawa M., Hatakeyama S., Shirane M., et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J. 18 (1999) 2401-2410
112. Latres E., Chiaur D.S., and Pagano M. The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 18 (1999) 849-854
113. Hart M., Concordet J.P., Lassot I., et al. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr. Biol. 9 (1999) 207-210
114. Ioannidis V., Beermann F., Clevers H., and Held W. The beta-catenin-TCF-1 pathway ensures CD4(+)CD8(+) thymocyte survival. Nat. Immunol. 2 (2001) 691-697
115. Scheller M., Huelsken J., Rosenbauer F., et al. Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. Nat. Immunol. 7 (2006) 1037-1047
116. Kirstetter P., Anderson K., Porse B.T., et al. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat. Immunol. 7 (2006) 1048-1056
117. Fukuchi M., Imamura T., Chiba T., et al. Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. Mol. Biol. Cell 12 (2001) 1431-1443
118. Wan M., Tang Y., and Tytler E.M. Smad4 protein stability is regulated by ubiquitin ligase SCF beta-TrCP1. J. Biol. Chem. 279 (2004) 14484-14487
119. Liang W., and Head-Gordon M. An exact reformulation of the diagonalization step in electronic structure calculations as a set of second order nonlinear equations. J. Chem. Phys. 120 (2004) 10379-10384
120. Hilton D.J., Richardson R.T., Alexander W.S., et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 114-119
121. Yoshimura A., Naka T., and Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev., Immunol. 7 (2007) 454-465
122. Wormald S., and Hilton D.J. The negative regulatory roles of suppressor of cytokine signaling proteins in myeloid signaling pathways. Curr. Opin. Hematol. 14 (2007) 9-15
123. Verdier F., Chretien S., Muller O., et al. Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein. J. Biol. Chem. 273 (1998) 28185-28190
124. Ryo A., Suizu F., Yoshida Y., et al. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell 12 (2003) 1413-1426
125. Mansell A., Smith R., Doyle S.L., et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat. Immunol. 7 (2006) 148-155
126. Ungureanu D., Saharinen P., Junttila I., et al. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol. Cell. Biol. 22 (2002) 3316-3326
127. Ihle J.N., and Gilliland D.G. Jak2: normal function and role in hematopoietic disorders. Curr. Opin. Genet. Dev. 17 (2007) 8-14
128. De Sepulveda P., Ilangumaran S., and Rottapel R. Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J. Biol. Chem. 275 (2000) 14005-14008
129. Tybulewicz V.L. Vav-family proteins in T-cell signalling. Curr. Opin. Immunol. 17 (2005) 267-274
130. Swat W., and Fujikawa K. The Vav family: at the crossroads of signaling pathways. Immunol. Res. 32 (2005) 259-265
131. Liu E., Cote J.F., and Vuori K. Negative regulation of FAK signaling by SOCS proteins. EMBO J. 22 (2003) 5036-5046
132. Mitra S.K., Hanson D.A., and Schlaepfer D.D. Focal adhesion kinase: in command and control of cell motility. Nat. Rev., Mol. Cell Biol. 6 (2005) 56-68
133. Orr S.J., Morgan N.M., Elliott J., et al. CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood 109 (2007) 1061-1068
134. Piessevaux J., Lavens D., Montoye T., et al. Functional cross-modulation between SOCS proteins can stimulate cytokine signaling. J. Biol. Chem. 281 (2006) 32953-32966
135. Erkeland S.J., Aarts L.H., Irandoust M., et al. Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling. Oncogene 26 (2007) 1985-1994
136. Guibal F.C., Moog-Lutz C., Smolewski P., et al. ASB-2 inhibits growth and promotes commitment in myeloid leukemia cells. J. Biol. Chem. 277 (2002) 218-224
137. Moog-Lutz C., Cave-Riant F., Guibal F.C., et al. JAML, a novel protein with characteristics of a junctional adhesion molecule, is induced during differentiation of myeloid leukemia cells. Blood 102 (2003) 3371-3378
138. Kohroki J., Fujita S., Itoh N., et al. ATRA-regulated Asb-2 gene induced in differentiation of HL-60 leukemia cells. FEBS Lett. 505 (2001) 223-228
139. Heuze M.L., Guibal F.C., Banks C.A., et al. ASB2 is an Elongin BC-interacting protein that can assemble with Cullin 5 and Rbx1 to reconstitute an E3 ubiquitin ligase complex. J. Biol. Chem. 280 (2005) 5468-5474
140. Zhang Y., Morrone G., Zhang J., et al. CUL-4A stimulates ubiquitylation and degradation of the HOXA9 homeodomain protein. EMBO J. 22 (2003) 6057-6067
141. Hatakeyama S., and Nakayama K.I. U-box proteins as a new family of ubiquitin ligases. Biochem. Biophys. Res. Commun. 302 (2003) 635-645
142. Ballinger C.A., Connell P., Wu Y., et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol. 19 (1999) 4535-4545
143. Patterson C. A new gun in town: the U box is a ubiquitin ligase domain. Sci. STKE 2002 (2002) PE4
144. Li L., Xin H., Xu X., et al. CHIP mediates degradation of Smad proteins and potentially regulates Smad-induced transcription. Mol. Cell. Biol. 24 (2004) 856-864
145. Xin H., Xu X., Li L., et al. CHIP controls the sensitivity of transforming growth factor-beta signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation. J. Biol. Chem. 280 (2005) 20842-20850
146. Reinstein E., and Ciechanover A. Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann. Intern. Med. 145 (2006) 676-684
147. Hoeller D., Hecker C.M., and Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat. Rev., Cancer 6 (2006) 776-788
148. Guardavaccaro D., and Pagano M. Oncogenic aberrations of cullin-dependent ubiquitin ligases. Oncogene 23 (2004) 2037-2049
149. Valk P.J., Verhaak R.G., Beijen M.A., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350 (2004) 1617-1628
150. Erkeland S.J., Valkhof M., Heijmans-Antonissen C., et al. Large-scale identification of disease genes involved in acute myeloid leukemia. J. Virol. 78 (2004) 1971-1980
151. Frantsve J., Schwaller J., Sternberg D.W., et al. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol. Cell. Biol. 21 (2001) 3547-3557
152. Rottapel R., Ilangumaran S., Neale C., et al. The tumor suppressor activity of SOCS-1. Oncogene (2002) 4351-4362
153. Hatirnaz O., Ure U., Ar C., et al. The SOCS-1 gene methylation in chronic myeloid leukemia patients. Am. J. Hematol. 82 (2007) 729-730
154. Chen C.Y., Tsay W., Tang J.L., et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer 37 (2003) 300-305
155. Ekmekci C.G., Gutierrez M.I., Siraj A.K., et al. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am. J. Hematol. 77 (2004) 233-240
156. Watanabe D., Ezoe S., Fujimoto M., et al. Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br. J. Haematol. 126 (2004) 726-735
157. Liu T.C., Lin S.F., Chang J.G., et al. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br. J. Haematol. 123 (2003) 654-661
158. Brakensiek K., Langer F., Schlegelberger B., et al. Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br. J. Haematol. 130 (2005) 209-217
159. Johan M.F., Bowen D.T., Frew M.E., et al. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br. J. Haematol. 129 (2005) 60-65
160. Wu S.J., Yao M., Chou W.C., et al. Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br. J. Haematol. 135 (2006) 317-323
161. Galm O., Yoshikawa H., Esteller M., et al. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101 (2003) 2784-2788
162. Chim C.S., Fung T.K., Cheung W.C., et al. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103 (2004) 4630-4635
163. Reddy J., Shivapurkar N., Takahashi T., et al. Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 24 (2005) 732-736
164. Chim C.S., Wong K.Y., Loong F., and Srivastava G. SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia 18 (2004) 356-358
165. Melzner I., Bucur A.J., Bruderlein S., et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 105 (2005) 2535-2542
166. Melzner I., Weniger M.A., Bucur A.J., et al. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int. J. Cancer 118 (2006) 1941-1944
167. Weniger M.A., Melzner I., Menz C.K., et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25 (2006) 2679-2684
168. Hann S.R., and Eisenman R.N. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol. Cell. Biol. 4 (1984) 2486-2497
169. Salghetti S.E., Kim S.Y., and Tansey W.P. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J. 18 (1999) 717-726
170. Bhatia K., Huppi K., Spangler G., et al. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat. Genet 5 (1993) 56-61
171. Clark H.M., Yano T., Otsuki T., et al. Mutations in the coding region of c-MYC in AIDS-associated and other aggressive lymphomas. Cancer Res. 54 (1994) 3383-3386
172. Yada M., Hatakeyama S., Kamura T., et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 23 (2004) 2116-2125
173. Welcker M., Orian A., Jin J., et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9085-9090
174. Bahram F., von der Lehr N., Cetinkaya C., and Larsson L.G. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95 (2000) 2104-2110
175. Papas T.S., and Lautenberger J.A. Sequence curiosity in v-myc oncogene. Nature 318 (1985) 237
176. Frykberg L., Graf T., and Vennstrom B. The transforming activity of the chicken c-myc gene can be potentiated by mutations. Oncogene 1 (1987) 415-422
177. Symonds G., Hartshorn A., Kennewell A., et al. Transformation of murine myelomonocytic cells by myc: point mutations in v-myc contribute synergistically to transforming potential. Oncogene 4 (1989) 285-294
178. Henriksson M., Bakardjiev A., Klein G., and Luscher B. Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene 8 (1993) 3199-3209
179. Pulverer B.J., Fisher C., Vousden K., et al. Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 9 (1994) 59-70
180. Imai Y., Kurokawa M., Izutsu K., et al. Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. Oncogene 20 (2001) 88-96
181. Yang L., Wang N., Tang Y., et al. Acute myelogenous leukemia-derived SMAD4 mutations target the protein to ubiquitin-proteasome degradation. Human Mutat. 27 (2006) 897-905
182. Liang M., Liang Y.Y., Wrighton K., et al. Ubiquitination and proteolysis of cancer-derived Smad4 mutants by SCFSkp2. Mol. Cell. Biol. 24 (2004) 7524-7537
183. Xu J., and Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4820-4825
184. Maurice D., Pierreux C.E., Howell M., et al. Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability. J. Biol. Chem. 276 (2001) 43175-43181
185. Moren A., Hellman U., Inada Y., et al. Differential ubiquitination defines the functional status of the tumor suppressor Smad4. J. Biol. Chem. 278 (2003) 33571-33582